AR063318A1 - Pirazoliltienopiridinas terapeuticas - Google Patents
Pirazoliltienopiridinas terapeuticasInfo
- Publication number
- AR063318A1 AR063318A1 ARP070104581A ARP070104581A AR063318A1 AR 063318 A1 AR063318 A1 AR 063318A1 AR P070104581 A ARP070104581 A AR P070104581A AR P070104581 A ARP070104581 A AR P070104581A AR 063318 A1 AR063318 A1 AR 063318A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- independently selected
- group
- thieno
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 24
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- -1 thieno [3,2-c] pyridinyl Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Son utiles como agentes terapéuticos en el tratamiento de trastornos mediados por TGF, incluyendo el cáncer y trastornos fibroticos. También se proporcionan composiciones farmacéuticas que comprenden uno o más compuestos de formula (1). Reivindicacion 1:Un compuesto caracterizado porque es de formula 1 o su sal farmacéuticamente aceptable, en la que: R1 es un tieno[3,2-c]piridinilo, un tieno[3,2-b]piridinilo, un tieno[2,3-c]piridinilo o un tieno[2,3-b]piridinilo, cada uno de los cuales puede estar opcionalmente sustituido con uno a tres sustituyentes, seleccionados cada uno independientemente del grupo que consiste en: alquilo C1-3, alquil C1-3-S-alquilo C1-3, -S-alquilo C1-3, alquil C1-3-O-alquilo C1-3, -O-alquilo C1-3, - C(O)O-alquilo C1-3, -C(O)O-H, -C(O)NR30R31, halogeno, -CN, -OH, en la que R30 y R31 se seleccionan cada uno independientemente del grupo que consiste en: H, y alquil C1-3-OH, alquilo C1-3, halogeno, y -O-alquilo C1-3; R2 y R3 se seleccionan independientemente del grupo que consiste en: hidrogeno, alquilo C1-3, alquil C1-3-S-alquilo C1-3, -S-alquilo C1-3, alquil C1-3-O-alquilo C1-3, -O-alquilo C1-3, -C(O)O-alquilo C1-3. -C(O)O-H, -C(O)NR30R31, halogeno, -CN, -OH, y un cicloalquilo C3-6, en la que R30 y R31 se seleccionan cada uno independientemente del grupo que consiste en: H, y alquilo C1-3, o R2 y R3 pueden tomarse conjuntamente para formar un heteroarilo de 5 o 6 miembros, un fenilo, un cicloalquilo C4-6, o un heterocicloalquilo de 4-6 miembros, en la que dicho cicloalquilo C4-6 o heterocicloalquilo de 4-6 miembros puede estar opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente de halogeno, -OH, oxo, y alquilo C1-3;. en la que dicho heteroarilo de 5 o 6 miembros o fenilo puede estar opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente de halogeno, -CN, -OH, -O-alquilo C1-3 y alquilo C1-3; y R4, R5, R6, y R7 se seleccionan del grupo que consiste en: H, OH, cicloalquilo C3, alquilo C1-3, alquil C1-3-S-alquilo C1-3, -S-alquilo C1-3, alquil C1-3-O-alquilo C1-3, -O-alquilo C1-3, -C(O)O-alquilo C1-3, -C(O)O-H, -C(O)NR30R31, halogeno, -CN, -OH, en la que R30 y R31 se seleccionan cada uno independientemente del grupo que consiste en: H, y alquilo C1-3-alquilo C1-3, -O-alquilo C1-3, y halogeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85198206P | 2006-10-16 | 2006-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063318A1 true AR063318A1 (es) | 2009-01-21 |
Family
ID=38962671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104581A AR063318A1 (es) | 2006-10-16 | 2007-10-16 | Pirazoliltienopiridinas terapeuticas |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US7964612B2 (es) |
| EP (2) | EP2527345B1 (es) |
| JP (1) | JP5443988B2 (es) |
| KR (1) | KR20090066297A (es) |
| CN (1) | CN101528752A (es) |
| AR (1) | AR063318A1 (es) |
| AU (1) | AU2007311560B2 (es) |
| CA (1) | CA2666603C (es) |
| CL (1) | CL2007002916A1 (es) |
| ES (2) | ES2435430T3 (es) |
| IL (1) | IL197750A0 (es) |
| MX (1) | MX2009003157A (es) |
| NO (1) | NO20091247L (es) |
| TW (1) | TW200825094A (es) |
| UY (1) | UY30641A1 (es) |
| WO (1) | WO2008047198A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2666603C (en) | 2006-10-16 | 2013-08-06 | Pfizer Products Inc. | Therapeutic pyrazolyl thienopyridines and uses thereof for treating tgf.beta. mediated conditions |
| JP2011509156A (ja) | 2008-01-08 | 2011-03-24 | イェール ユニバーシティ | 血管移植片の開存性を促進するための組成物および方法 |
| FR2949468B1 (fr) * | 2009-08-28 | 2011-09-30 | Sanofi Aventis | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique |
| PT2382205E (pt) | 2008-12-29 | 2014-07-28 | Sanofi Sa | Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, sua preparação e sua aplicação terapêutica como activadores de hif |
| FR2940652B1 (fr) * | 2008-12-29 | 2011-02-11 | Sanofi Aventis | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique |
| DK2382215T3 (da) | 2008-12-29 | 2014-10-27 | Sanofi Sa | Derivater af 2-pyridin-2-yl-pyrazol-3(2h)-on, fremstilling og terapeutisk anvendelse heraf |
| CN102448951B (zh) | 2009-04-06 | 2017-05-10 | 安吉奥斯医药品有限公司 | 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法 |
| EP2448581B1 (en) | 2009-06-29 | 2016-12-07 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
| PT2448582T (pt) | 2009-06-29 | 2017-07-10 | Agios Pharmaceuticals Inc | Compostos e composições terapêuticas |
| KR20130038224A (ko) * | 2010-03-15 | 2013-04-17 | 가부시키가이샤 구라레 | 티에노피리딘 유도체 및 그 제조 방법, 그리고 그것을 사용한 유기 반도체 디바이스 |
| JP5743418B2 (ja) * | 2010-04-09 | 2015-07-01 | Ｏａｔアグリオ株式会社 | 新規なピラゾール化合物、その製造方法及び有害生物防除剤 |
| CN103260702B (zh) | 2010-10-28 | 2018-07-27 | 帕西拉制药有限公司 | 非甾体类抗炎药的缓释制剂 |
| MX2013006858A (es) | 2010-12-16 | 2013-07-29 | Hoffmann La Roche | Compuesto triciclicos inhibidores de la pi3k y metodos de uso. |
| JP5837091B2 (ja) | 2010-12-17 | 2015-12-24 | アジオス ファーマシューティカルズ， インコーポレイテッド | ピルビン酸キナーゼｍ２（ｐｋｍ２）調節剤としての新規ｎ−（４−（アゼチジン−１−カルボニル）フェニル）−（ヘテロ−）アリールスルホンアミド誘導体 |
| US9328077B2 (en) | 2010-12-21 | 2016-05-03 | Agios Pharmaceuticals, Inc | Bicyclic PKM2 activators |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| BR112013020329A2 (pt) * | 2011-02-09 | 2016-08-02 | Hoffmann La Roche | compostos heterocíclicos como inibidores da pi3-quinase |
| WO2012151440A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
| CN108451955B (zh) | 2011-05-03 | 2022-02-01 | 安吉奥斯医药品有限公司 | 用于治疗的丙酮酸激酶活化剂 |
| WO2012167261A2 (en) | 2011-06-03 | 2012-12-06 | Yale University | Compositions and methods for treating and preventing neointimal stenosis |
| CN102660253B (zh) * | 2012-03-07 | 2014-05-21 | 泰山医学院 | 一种吡唑啉衍生物类Ni2+荧光探针及其应用 |
| ES2834959T3 (es) | 2012-12-06 | 2021-06-21 | Celgene Quanticel Res Inc | Inhibidores de histona desmetilasa |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| CN105324371A (zh) * | 2013-06-20 | 2016-02-10 | 巴斯夫欧洲公司 | 由吡啶基肼制备吡啶基吡唑化合物及其衍生物的方法 |
| SMT202300344T1 (it) | 2015-06-11 | 2023-11-13 | Agios Pharmaceuticals Inc | Metodi di utilizzo degli attivatori della piruvato chinasi |
| CA3007631A1 (en) | 2015-12-11 | 2017-06-15 | Research Institute At Nationwide Children's Hospital | Optimized patient specific non-linear tissue engineered vascular grafts |
| KR102434226B1 (ko) * | 2016-06-30 | 2022-08-19 | 한미약품 주식회사 | Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도 |
| KR20190057108A (ko) * | 2016-09-30 | 2019-05-27 | 인터셉트 파마슈티컬즈, 인크. | 담즙산 유도체의 결정형 |
| WO2018094253A1 (en) | 2016-11-18 | 2018-05-24 | Pacira Pharmaceuticals, Inc. | Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same |
| CA3186628A1 (en) * | 2020-06-30 | 2022-01-06 | Dermira, Inc. | Ror.gamma.t inhibitors and topical uses thereof |
| CN116249692B (zh) * | 2020-09-28 | 2024-08-23 | 四川科伦博泰生物医药股份有限公司 | 吡唑类化合物及其制备方法和用途 |
| IL308129A (en) * | 2021-05-03 | 2023-12-01 | Thirona Bio Inc | Methods for treating lung disease with an ALK-5 inhibitor (TGF BETA R1) |
| CA3256836A1 (en) * | 2022-04-29 | 2023-11-02 | Mannkind Corporation | METHOD AND COMPOSITION FOR THE TREATMENT OF LUNG DISEASES |
| WO2025090562A1 (en) * | 2023-10-25 | 2025-05-01 | Thirona Bio, Inc. | Formulations of alk-5 kinase inhibitors and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0102672D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| UA80571C2 (en) * | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
| SE0300120D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| CL2004000234A1 (es) * | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| AR048669A1 (es) * | 2004-03-03 | 2006-05-17 | Syngenta Ltd | Derivados biciclicos de bisamida |
| AU2005280167A1 (en) * | 2004-08-31 | 2006-03-09 | Biogen Idec Ma Inc. | Pyrimidinylpyrazoles as TGF-beta inhibitors |
| EP1812450A2 (en) * | 2004-11-10 | 2007-08-01 | Eli Lilly And Company | Tgf-beta inhibitors |
| CA2666603C (en) | 2006-10-16 | 2013-08-06 | Pfizer Products Inc. | Therapeutic pyrazolyl thienopyridines and uses thereof for treating tgf.beta. mediated conditions |
-
2007
- 2007-10-04 CA CA2666603A patent/CA2666603C/en active Active
- 2007-10-04 JP JP2009532905A patent/JP5443988B2/ja active Active
- 2007-10-04 EP EP12006019.9A patent/EP2527345B1/en active Active
- 2007-10-04 AU AU2007311560A patent/AU2007311560B2/en not_active Expired - Fee Related
- 2007-10-04 ES ES07825309T patent/ES2435430T3/es active Active
- 2007-10-04 MX MX2009003157A patent/MX2009003157A/es not_active Application Discontinuation
- 2007-10-04 EP EP07825309.3A patent/EP2074128B1/en active Active
- 2007-10-04 CN CNA2007800386503A patent/CN101528752A/zh active Pending
- 2007-10-04 WO PCT/IB2007/002994 patent/WO2008047198A1/en not_active Ceased
- 2007-10-04 KR KR1020097007709A patent/KR20090066297A/ko not_active Ceased
- 2007-10-04 ES ES12006019.9T patent/ES2559521T3/es active Active
- 2007-10-10 CL CL200702916A patent/CL2007002916A1/es unknown
- 2007-10-12 UY UY30641A patent/UY30641A1/es not_active Application Discontinuation
- 2007-10-12 US US11/871,311 patent/US7964612B2/en active Active
- 2007-10-12 TW TW096138215A patent/TW200825094A/zh unknown
- 2007-10-16 AR ARP070104581A patent/AR063318A1/es active IP Right Grant
-
2009
- 2009-03-23 IL IL197750A patent/IL197750A0/en unknown
- 2009-03-25 NO NO20091247A patent/NO20091247L/no not_active Application Discontinuation
-
2011
- 2011-05-20 US US13/112,520 patent/US8455512B2/en active Active
-
2013
- 2013-04-17 US US13/864,457 patent/US9090625B2/en active Active
-
2015
- 2015-03-03 US US14/637,097 patent/US9260450B2/en active Active
-
2016
- 2016-01-14 US US14/995,556 patent/US9938289B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160200735A1 (en) | 2016-07-14 |
| CN101528752A (zh) | 2009-09-09 |
| EP2527345B1 (en) | 2015-12-16 |
| EP2074128B1 (en) | 2013-08-14 |
| JP2010506895A (ja) | 2010-03-04 |
| KR20090066297A (ko) | 2009-06-23 |
| AU2007311560A1 (en) | 2008-04-24 |
| US20150175624A1 (en) | 2015-06-25 |
| JP5443988B2 (ja) | 2014-03-19 |
| ES2435430T3 (es) | 2013-12-19 |
| AU2007311560B2 (en) | 2011-04-21 |
| WO2008047198A1 (en) | 2008-04-24 |
| US9090625B2 (en) | 2015-07-28 |
| CA2666603A1 (en) | 2008-04-24 |
| US8455512B2 (en) | 2013-06-04 |
| US7964612B2 (en) | 2011-06-21 |
| IL197750A0 (en) | 2009-12-24 |
| NO20091247L (no) | 2009-04-23 |
| MX2009003157A (es) | 2009-04-03 |
| UY30641A1 (es) | 2008-05-31 |
| US9938289B2 (en) | 2018-04-10 |
| TW200825094A (en) | 2008-06-16 |
| ES2559521T3 (es) | 2016-02-12 |
| CA2666603C (en) | 2013-08-06 |
| US20140031385A1 (en) | 2014-01-30 |
| US9260450B2 (en) | 2016-02-16 |
| EP2074128A1 (en) | 2009-07-01 |
| US20080090861A1 (en) | 2008-04-17 |
| EP2527345A1 (en) | 2012-11-28 |
| CL2007002916A1 (es) | 2008-04-18 |
| US20110224251A1 (en) | 2011-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063318A1 (es) | Pirazoliltienopiridinas terapeuticas | |
| AR123089A2 (es) | Compuesto de piridinona | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| PE20171240A1 (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
| PE20170144A1 (es) | 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet | |
| PE20081844A1 (es) | DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| CL2017002610A1 (es) | Compuestos derivados de triazolopiridina hidrogenadas, inhibidores p2x7, composición farmacéutica que los comprende; proceso de preparación de estos; y su uso en el tratamiento de enfermedades oseas, sns, cardiovasculares, entre otras (divisional de cl 2655-2015) | |
| AR086019A1 (es) | COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| ES2603931T3 (es) | Compuestos de triazolo | |
| AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos | |
| AR094876A1 (es) | Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo | |
| CO6300861A2 (es) | Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos | |
| AR095708A1 (es) | Indazoles sustituidos con diaminoheteroarilo | |
| AR050186A1 (es) | Derivados de amino-piperidina, su preparacion y su aplicacion en terapeutica. | |
| CO6551713A2 (es) | Derivados de difenil -pirazolopiridinas, su preparación y su aplicación como moduladores del receptor nuclear not | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| AR065891A1 (es) | Derivados de piridina y pirimidina como antagonistas del mglur2 | |
| AR098647A1 (es) | Inhibidores de serina / treonina cinasa | |
| PE20141940A1 (es) | Compuestos triciclicos, composiciones que los comprenden y usos de los mismos | |
| PE20190980A1 (es) | Compuestos terapeuticos y metodos para utilizarlos | |
| AR051334A1 (es) | Derivados de 2- amido-4-feniltiazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FG | Grant, registration |